睿知中国医院研究地图
候选清单

即将招募鼻咽癌不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Impacted Tooth Management and Osteoradionecrosis Risk in NPC

ClinicalTrials.gov 上登记的一项鼻咽癌开放试验,由广西医科大学第一附属医院牵头,本站收录的另外 6 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically confirmed non-keratinizing nasopharyngeal carcinoma, including differentiated or undifferentiated subtype (WHO type II or III).

    入选标准第 3 条

  3. Newly diagnosed, previously untreated nasopharyngeal carcinoma with stage T1-4N0-3M0 according to the 9th edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) staging system.

    入选标准第 4 条

  4. History of active tuberculosis more than 1 year previously without documented completion of standard anti-tuberculosis treatment.

    排除标准第 21 条

  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

    入选标准第 1 条

  6. History of active malignancy or other malignant tumors diagnosed within the previous 5 years, except for adequately treated non-melanoma skin cancer or carcinoma in situ.

    排除标准第 6 条

    Positive hepatitis B surface antigen (HBsAg) with hepatitis B virus DNA >1,000 copies/mL.

    排除标准第 17 条

    Active hepatitis C virus infection (positive HCV RNA).

    排除标准第 18 条

    Human immunodeficiency virus (HIV) infection or diagnosis of acquired immunodeficiency syndrome (AIDS).

    排除标准第 19 条

    Active tuberculosis within the previous 1 year.

    排除标准第 20 条

  7. Pregnant or breastfeeding women.

    排除标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07764887,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  2. Age 18-75 years, regardless of sex.
  3. Histologically confirmed non-keratinizing nasopharyngeal carcinoma, including differentiated or undifferentiated subtype (WHO type II or III).
  4. Newly diagnosed, previously untreated nasopharyngeal carcinoma with stage T1-4N0-3M0 according to the 9th edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) staging system.
  5. Presence of permanent dentition with at least one impacted third molar.
  6. Adequate bone marrow function, defined as white blood cell count ≥4.0 × 10⁹/L, platelet count ≥100 × 10⁹/L, and hemoglobin ≥90 g/L.
  7. Adequate hepatic function, defined as alanine aminotransferase and aspartate aminotransferase ≤2.5 × the upper limit of normal (ULN), and total bilirubin ≤1.5 × ULN.
  8. Adequate renal function, defined as blood urea nitrogen and serum creatinine ≤1.5 × ULN, or creatinine clearance ≥60 mL/min.
  9. Coagulation function within normal limits.
  10. Written informed consent provided, with willingness and ability to comply with study visits, treatment plans, laboratory assessments, and other study procedures.

排除标准:Exclusion Criteria:

  1. Histopathological diagnosis other than WHO type II or III nasopharyngeal carcinoma.
  2. Impacted third molars with recurrent pericoronitis or inflammation due to incomplete eruption.
  3. Fully erupted third molars with dental caries involving the pulp.
  4. Impacted third molars with radiographic evidence of periapical or periodontal inflammation.
  5. Third molars completely impacted within the jawbone.
  6. History of active malignancy or other malignant tumors diagnosed within the previous 5 years, except for adequately treated non-melanoma skin cancer or carcinoma in situ.
  7. Previous chemotherapy, surgery (except diagnostic procedures), radiotherapy, or other antitumor treatment for nasopharyngeal carcinoma or cervical lesions.
  8. Patients receiving palliative treatment.
  9. Pregnant or breastfeeding women.
  10. Severe uncontrolled cardiovascular or cerebrovascular diseases.
  11. Severe hepatic or renal dysfunction.
  12. Uncontrolled diabetes mellitus.
  13. Severe osteoporosis, medication-related osteonecrosis/osteomyelitis, or chronic diseases requiring long-term systemic corticosteroid therapy.
  14. Other severe chronic debilitating diseases that may increase study risk or affect study compliance.
  15. History of drug abuse or alcohol dependence.
  16. Uncontrolled psychiatric disorders or inability to provide legally valid informed consent.
  17. Positive hepatitis B surface antigen (HBsAg) with hepatitis B virus DNA >1,000 copies/mL.
  18. Active hepatitis C virus infection (positive HCV RNA).
  19. Human immunodeficiency virus (HIV) infection or diagnosis of acquired immunodeficiency syndrome (AIDS).
  20. Active tuberculosis within the previous 1 year.
  21. History of active tuberculosis more than 1 year previously without documented completion of standard anti-tuberculosis treatment.
  22. Any other medical, psychological, social, or laboratory condition that, in the investigator's judgment, may compromise participant safety, interfere with study procedures, affect protocol compliance, or result in premature withdrawal from the study.
  23. Refusal or inability to provide written informed consent.

引自 ClinicalTrials.gov, NCT07764887, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07764887,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07764887